Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Status:	Completed
Conditions:	Hepatitis
Therapuetic Areas:	Immunology / Infectious Diseases
Healthy:	No
Age Range:	18 - Any
Updated:	4/21/2016
Start Date:	July 2012
End Date:	September 2014

A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, With and Without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naïve Genotype 2 and 3 Chronic Hepatitis C Subjects

The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon
Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus
Ribavirin and Daclatasvir will be safe and effective for treatment of hepatitis C compared
to 24 weeks of treatment with Pegylated Interferon Alfa-2a plus Ribavirin

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Chronic hepatitis C, Genotype 2 or 3

- Naïve to prior anti-HCV therapy

Exclusion Criteria:

- Infected with HCV other than Genotype 2 or 3

- Positive Hepatitis B surface antigen (HBsAg), or Human immunodeficiency virus-1
(HIV-1)/HIV-2 antibody at screening

- Evidence of liver disease other than HCV

- Active substance abuse

- Evidence of decompensated cirrhosis

We found this trial at

sites

Henry Ford Hospital

2799 W Grand Blvd
Detroit, Michigan 48202

(313) 916-2600